108 results about "AMI - Acute myocardial infarction" patented technology

A method for differentiating acute myocardial infarction (AMI) from other ECG abnormalities. The method is performed by modeling selected ECG confounders that tend to obscure AMI evidence in the ECG waveform, and by purging a subject's ECG waveform of the effect(s) of these confounders through linking selected confounder models with an appropriate, computer-implementable purge algorithm.

The invention discloses an acute myocardial infarction diagnosis-oriented biosensor and a preparation method thereof. The sensor comprises a sensor matrix with a field effect tube (FET) structure, and a micro channel system layer, wherein the sensor matrix comprises a silicon-on-insulator (SOI) silicon chip; the surface of the silicon chip is provided with a passivation layer, silicon nanowires of which the surfaces are coupled with monoclonal antibody modified by acute myocardial infarction marker protein, and electrodes; at least local surfaces of the nanowires are exposed in a micro channel in the micro channel system layer; the micro channel is communicated with a sample solution inlet and a sample solution outlet on the micro channel system layer; and the sensor is prepared by a micro-nano processing method. The sensor can detect various marker proteins in serum by an electrical measurement means so as to acquire the degree of myocardial infarction attack. The biosensor can quickly and sensitively detect the myocardial infarction, has high response speed and diagnostic rate, and is suitable for the field of clinical medical detection.

The invention relates to application of E1A-simulated gene cellular repressor (CREG) protein, in particular to application of CREG protein or active fragment thereof in preparation of drug used for preventing and/or treating acute myocardial infarction, heart failure after acute myocardial infarction and/or ventricular remodeling after the same. The invention further relates to application of recombinant vector or recombinant cell expressing the CREG protein or the active fragment thereof in preparation of the drug used for preventing and/or treating acute myocardial infarction, heart failure after acute myocardial infarction and/or ventricular remodeling after the same.

The invention belongs to the immunology field in medicine and particularly relates to a B-cell epitope peptide of H-FABP and applications of an antibody thereof. The epitope peptide is shown in SEQ ID NO.5 and can be used for preparing hybridoma cell lines and secreting a corresponding monoclonal antibody. The monoclonal antibody is capable of being used for preparing a diagnostic reagent which is used for detecting the H-FABP and prepared on a large scale, provided with purity higher than 96%, good in specificity and the like; and a detection titer of a purified antibody through an indirect enzyme-linked immunosorbent assay (ELISA) reaches 1:256,000. Monoclonal antibodies and polyclonal antibodies prepared through the epitope peptide can be used for H-FABP detection in patients' blood, and a foundation is laid for early diagnosis of acute myocardial infarction (AMI).

The invention relates to the technical field of genetic engineering, and discloses long-chain non-encoded RNA ENST00000581794.1 as well as a kit and an application thereof. The sequence of the long-chain non-encoded RNA ENST00000581794.1 is as shown in SEQ ID NO:1. A long-chain non-encoded expression profile chip technique is used, and a piece of lncRNA ENST00000581794.1 which is remarkably and highly expressed in blood of patients suffering from acute myocardial infarction can be screened through differential analysis, so that study on pathogenesis of acute myocardial infarction is further enriched.

The invention discloses application of EMD638683 in protection of the heart suffering from acute myocardial infarction. The invention provides application of EMD638683 in preparation of products having the following functions: 1) prevention and/or treatment of myocardial infarction of animals; 2) prevention and/or treatment of heart failure caused by myocardial infarction of animals; and 3) inhibition of the expression of SGK1 protein in cardiac muscle tissue after myocardial infarction of animals. Experimental results of the invention prove that EMD638683 has treatment effect on mice with myocardial infarction, and experimental data is provided for clinical application of EMD638683 in treatment of myocardial infarction. The EMD638683 is of important theoretical significance to research on and development of medicines used for preventing and treating heart failure caused by myocardial infarction and has good application prospects.

The invention relates to the technical field of biological engineering myocardial infarction related genes, and relates to a lncRNA NR-047662.2 and an in-vitro detection reagent, preparation or kit, applications and a detection method; the long non-coding RNA NR-047662.2 has a nucleic acid sequence as shown in SEQ ID No:1. The long non-coding RNA NR-047662.2 can provide new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction, and further enriches the research on a pathogenesis of acute myocardial infarction.

The invention relates to a natriuretic peptide from a snake and a gene encoding the polypeptide. The natriuretic peptide disclosed by the invention is the natriuretic peptide from dendroaspis angusticeps. The natriuretic peptide disclosed by the invention is the brand new natriuretic peptide and a new member in a natriuretic peptide family, and is further called as GNP, namely G type natriuretic peptide. The invention further provides a preparation method of the recombinant natriuretic peptide. The natriuretic peptide provided by the invention comprises the recombinant natriuretic peptide and an artificially synthesized natriuretic peptide, which can be applied to preparation of medicaments for treating patients with acute heart failure, acute decompensated heart failure, acute myocardial infarction after coronary intervention, chronic heart failure, and acute anterior wall myocardial infarction with systolic heart failure of old people.

The invention relates to a prediction method and system for the survival rate of an acute myocardial infarction patient within 5 years. The method comprises the steps: acquiring clinical data of the acute myocardial infarction patient during hospital admission; establishing a prediction model according to the clinical data, establishing a column diagram of the survival rate within 5 years, calculating a total risk score, and then calculating a prediction value of the survival rate of the patient within 5 years; and outputting a predicted value of the survival outcome occurrence probability ofthe patient within 5 years. External verification proves that the method is suitable for Chinese people, statistical analysis is carried out by combining various potential risk factors influencing poor prognosis such as hospitalization baseline vital signs of acute myocardial infarction patients, operations and drug intervention, laboratory examination and imaging examination, factors related to the survival rate within 5 years are screened out, a prediction system for the survival rate of the acute myocardial infarction patient within 5 years is established, and a risk quantitative value is provided for clinicians to predict the survival rate of the acute myocardial infarction patient within 5 years more comprehensively and accurately.

The invention provides an lncRNA marker and application thereof in acute myocardial infarction diagnosis. The LncRNA marker is LINC01104, and the expression quantity of the LINC01104 in an acute myocardial infarction patient is lower than that of a normal person. The invention further discloses a fluorescent quantitative PCR kit for detecting acute myocardial infarction. The kit contains a reagentfor measuring expression of the LINC01104. Compared with a traditional biomarker, the LINC01104 marker has better tissue specificity and good stability, and the sensitivity and specificity of acute myocardial infarction diagnosis can be greatly improved.

The invention provides application of MED6 genes serving as an acute myocardial infarction risk prediction marker. The MED6 genes or gene expression products are taken as a novel acute myocardial infarction risk prediction and diagnoses and treatment target. The MED6 genes and expression products thereof are used for preparing acute myocardial infarction risk prediction markers and diagnoses preparations and have important clinical application significance and development values.

The invention discloses a miRNA-208a amplification primer pair based on chain exchange amplification and a detection kit thereof. The amplification primer pair comprises a forward primer and a reverse primer; the forward primer is composed of a 5' end side balance sequence and a 3' end side amplification sequence, and the amplification sequence is homologous with the 5' end side sequence of miRNA-208a-3p; and the reverse primer is composed of a 5' end side amplification sequence and a 3' end side balance sequence, and the amplification sequence is complementary with the 3' end side sequence of the miRNA-208a-3p. After an isothermal amplification reaction of the miRNA-208a is completed, a running buffer solution is added, the mixture is uniformly mixed and dropwise added to a sample adding window of a test strip, and a fluorescence signal is detected after 2 minutes. The detection method provided by the invention can be completed within 1 hour. The miRNA-208a detection method is simple, convenient, rapid and safe to operate, and an early molecular diagnosis detection method can be provided for acute myocardial infarction.

The present disclosure provides methods and compositions for treating coronary tissue damaged as a result of a cardiac disorder such as ischemia, acute myocardial infarction, vulnerable plaques, or reperfusion injury. Specifically, the cardiac disorder is treated using a multivalent molecule that is specific for a marker located, in or near the damaged coronary tissue and a marker located on a target cell (e.g., a stem cell). The multivalent molecule may be administered by intravenous injection, intra-arterial catheter, intramyocardial injection, or implantable device (e.g, stent).

The invention belongs to manufacture method and use method of rat tracheal intubation equipment, and particularly relates to a manufacture method and use method of tracheal intubation equipment of a rat acute myocardial infarction model. A needle core and an inner guide wire of the needle core are respectively a guide needle and a loach guide wire (Terumo super-slippery M-shaped loach guide wire in Japan) used for coronary artery intervention; the soft end of the guide wire penetrates through the tail end of the guide needle and is exposed from the head end of the guide needle by 0.4cm; and the redundant guide wire at the tail end of the guide needle is cut off. An outer-layer hose is prepared from an infusion needle of disposable venous infusion apparatus (Shanghai Youyu Medical EquipmentCo., Ltd., 0.5x20 infusion apparatus), wherein the length of the outer-layer hose is shorter than the length of a catheter needle by 0.3 cm, and the root of the hose is cut obliquely by a movable flap which accounting for 1/3 of the circumference of the hose. After anaesthesia, a rat is fixed and is subjected to skin preparation, a rat tongue is clamped out with a small tweezer, the tongue tip ispulled by a left hand, and a tracheal intubation pipe is hold by a right hand. A hard catheter needle at the head end of the tracheal intubation needle core is arranged at the root part of the rat tongue, and a trachea opening of the rat is searched by fine adjustment of the self-made tracheal intubation pipe under direct vision. The guide wire at the head end of the tracheal intubation pipe is sent in instantly when the trachea opening is opened, then the guide wire at the head end is inserted into the trachea opening by about 1cm through rotation, and the catheter needle is pulled out, wherein if the rat can breathe uniformly and smoothly, intubation is successful.

The invention discloses a fusion protein of MNK2 protein kinase and a cell-penetrating peptide, a hydrogel of the fusion protein, and an application of the fusion protein in promoting myocardial regeneration, and belongs to the technical field of biomedicine. The fusion protein includes an MNK2 protein kinase sequence and a cell-penetrating peptide sequence, after injection, the fusion protein canaffect the process of cardiomyocyte cell cycle, mitosis and DNA synthesis by activating key pathways of the myocardial regeneration, reduce myocardial infarction area and fibrosis, promote myocardialregeneration repair after acute myocardial infarction, and improve recovery of a cardiac function; at the same time, a three-dimensional network structure formed by liquid coagulation of the small-molecular hydrogel can provide mechanical support force for a ventricle and delay ventricular remodeling; and the porous structure of the small-molecular hydrogel facilitates growth of regenerated cardiomyocytes, thereby promoting myocardial repair.

The invention provides application of CD177 as a biomarker for detecting acute myocardial infarction, and relates to the technical field of biomedicine. The application can be used for predicting the attack of the acute myocardial infarction before the attack of the acute myocardial infarction to achieve the purpose of nipping in the bud, so that medical staff can better implement medical measures, the probability of sudden death of a patient due to the acute myocardial infarction is reduced The biomarker for detecting the acute myocardial infarction comprises CD177 protein and CD177 positive neutrophils, and the expression condition of the CD177 in a human body is used as a basis for judging the acute myocardial infarction. Compared with the original methods for detecting cardiac troponin T (cTnI), creatine kinase-MB (CK-MB) and the like as pathogenesis indexes of the acute myocardial infarction, the application has the advantages that the pathogenesis of the acute myocardial infarction can be predicted in advance, and a research direction is provided for predicting the pathogenesis time of the acute myocardial infarction in the future.

The invention discloses application of compound 5-bromo-2-(alpha-hydroxy amyl) sodium benzoate (BZP) in medicine for curing cardiovascular disease, and belongs to the field of medicinal chemistry. Experiments prove that BZP has a protective effect for acute and chronic myocardial ischemia reperfusion injuries of a mouse, so that the overall animal acute myocardial infarction area is reduced through BZP oral administration and intravenous injection, the myocardial infarction area of the acute ischemia reperfusion injury of the isolated perfusion heart of the mouse is reduced through BZP, the function of myocardial contraction is improved, and the haematological myocardial injury markers are reduced; moreover, the invention also relates to application for delaying a process of the conversionfrom myocardial hypertrophy to cardiac failure after chronic orally taken administration of BZP for acute myocardial infarction of the mouse and reducing ventricular remodeling caused by ischemic heart disease of the mouse, the therapeutic action of the cardiac function is improved obviously; moreover, the invention also relates to the transient effect of the compound BZP for reducing the blood pressure of the hypertension mouse (SHR mouse), and these results indicate that the BZP has effective research and development prospects of myocardial damage protection medicine for clinically acute and chronic myocardial infarctions.

The invention belongs to application of fasudil hydrochloride in preparation of a medicament for promoting in-vivo survival and repair of mesenchymal stem cells and a preparation of the fasudil hydrochloride, and provides application of fasudil hydrochloride in preparation of a medicament for promoting in-vivo survival and repair of mesenchymal stem cells, in particular application of fasudil hydrochloride in preparation of an auxiliary medicament for treating cardiovascular diseases by using mesenchymal stem cells and application in preparation of an auxiliary medicament for treating acute myocardium infarction by using mesenchymal stem cells. The formulation of the medicament containing the fasudil hydrochloride comprises capsules, tablets or injection. The application range of the fasudil hydrochloride is enlarged; and through the provided medicament, ROCK and downstream signals are directly inhibited, severe myocardial microenvironments of infarct post-inflammation, fibrosis and the like are improved, the in-vivo survival of transplanted cells is enhanced, the stem cells exert effects, the myocardium is repaired, the infarct area is reduced, and the cardiac function is improved.

The invention belongs to the technical field of biochemical medicines, and particularly relates to preparation of a lipoic acid-loaded nano-material and application of the lipoic acid-loaded nano-material in acute myocardial infarction diseases. An electrospinning technology is adopted, and a multi-layer lipoic acid-loaded PLGA nano-film material is synthesized by taking PLGA which is degraded at a controllable speed as a raw material to load lipoic acid; the nano-film material has better drug loading capacity and encapsulation efficiency, and also has a better drug release effect in a PBS (Phosphate Buffer Solution), so that the drug can be quickly and continuously released locally in a myocardial infarction area, and a good anti-oxidative stress treatment effect is achieved; when being applied to myocardial infarction treatment (namely being placed on the surface of myocardial infarction heart tissue in a pericardial cavity) as a cardiac functional patch, the medicine can improve ventricular remodeling, improve the cardiac function level, effectively relieve myocardial cell oxidative stress injury and improve the treatment effect of acute myocardial infarction.